CAS:1009119-64-5
1009119-64-5
CAS号：1009119-64-5
品名：达卡他韦daclatasvir
中文别名：N,N'-[[1,1'-联苯]-4,4'-二基双[1H-咪唑-5,2-二基-(2S)-2,1-吡咯烷二基[(1S)-1-(1-甲基乙基)-2-氧代-2,1-乙烷二基]]]双氨基甲酸C,C'-二甲酯;
英文别名：Carbamicacid,N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-,C,C'-dimethylester;N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamicacidC,C'-dimethylester;BMS-790052;EBP883;Daclatasvir;
分子式：C40H50N8O6
分子量：738.875
精确质量：738.385
Psa：174.64
UNII号：LI2427F9CI
密度：1.249
简介：Daclatasvir(USAN,formerlyBMS-790052,tradenameDaklinza)isadrugforthetreatmentofhepatitisC(HCV).ItwasdevelopedbyBristol-MyersSquibbandwasapprovedinEuropeon22August2014.DaklinzagaineditsFDAapprovalonJuly24,2015intheUnitedStates;itisapprovedforHepatitisCgenotype3infections.
蛋白酶
